TORONTO, March 22, 2018 (GLOBE NEWSWIRE) — Abba Medix Corp “Abba”, a subsidiary of Canada House Wellness Group Inc. (CSE:CHV) (“Canada House” or the “Company”) wishes to announce that it received its starting genetics yesterday. With forty-seven strains now in house, the experienced team at Abba will begin cultivation in the coming days. Abba will initially grow a variety of cannabis strains most sought by the thousands of medical cannabis patients of its sister company, Marijuana For Trauma.

“We’re excited to begin our cultivation efforts and provide Canada’s medical cannabis patients with exactly the high quality, premium product they require,” said Riley McGee, Abba’s President. “Planting our first crop is a great step towards fulfilling our passion for acquiring the very best genetics and growing them in the most favourable, technologically advanced, indoor environment for the benefit of those with a genuine medicinal need,” he added.

Abba’s genetics arrived yesterday, and Abba looks to have two lots of cannabis harvested and ready for Health Canada approval by mid-year, and anticipates receiving its License to Sell this summer.  It then expects to be in full production by October of this year.

At full production, Abba’s current grow operations are projected to produce more than 2,500 kg annually.

Canada House Wellness Group Inc.
Canada House is the parent company of Marijuana for Trauma Inc., Knalysis Technologies and Abba Medix Corp. The Company’s goal is to become a marketplace leader through strategic partnerships, mergers, and acquisitions to create a fully integrated cannabis therapy company. For more information please visit or

For further information, please contact:
Boom Capital Markets
Steve Low

Canada House Wellness Group, Inc.
Larry Bortles

Cautionary Statement Regarding Forward‐Looking Information. Certain statements within this news release pertaining to the Company constitute “forward‐looking statements”, within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and/or objectives, sales programs, forecasts and projections, assumptions, expectations, and/or beliefs of future performance, are “forward‐looking statements”. Such “forward‐looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward‐looking statements include, but are not limited to, statements with respect to the anticipated effects of the financing, regulatory changes, timeliness of government approvals for the granting of permits and licenses, changes in medical marijuana prices, actual operating performance of facilities, competition and other risks affecting the Company in particular and the medical marijuana industry generally, including those set out in the Company’s public disclosure record. The Company assumes no responsibility to update or revise forward‐looking information to reflect new events or circumstances unless required by law.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.